Lutris Pharma

Executive Summary

Lutris Pharma is an Israeli clinical-stage biotechnology company addressing a significant unmet need in oncology: the mitigation of cutaneous toxicities induced by EGFR inhibitor and radiation therapies. Its lead candidate, LUT014, is a topical formulation of a B-Raf inhibitor designed to reduce severe skin rashes and lesions that often lead to dose reductions or discontinuation of life-saving cancer treatments. By improving tolerability, LUT014 aims to enhance patient compliance and quality of life, potentially unlocking the full therapeutic benefit of EGFR inhibitors and radiotherapy. The company is currently advancing LUT014 through Phase 2 clinical trials, with a focus on demonstrating efficacy in reducing the incidence and severity of dermatologic adverse events. Lutris Pharma operates in a niche but growing market, as EGFR inhibitors are widely used in colorectal, lung, and head and neck cancers, and radiation therapy remains a cornerstone of cancer care. The company's differentiated approach—targeting the mechanistic pathway of B-Raf inhibition—could offer a novel solution where current supportive care options are limited. With a streamlined development path and potential for rapid adoption if pivotal results are positive, Lutris Pharma represents a promising investment opportunity in the oncology supportive care space. The company's progress in Phase 2 will be a critical value inflection point.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Topline Data for LUT014 in EGFR Inhibitor-Induced Dermatitis45% success
• Q4 2026Phase 2 Interim Data for LUT014 in Radiation Dermatitis35% success
• TBDStrategic Partnership or Licensing Deal for LUT01420% success